Latest filing published 08 Aug 2019 for ReShape Lifesciences Inc., €45k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Andrew P. Rasdal: trading record in brief
Andrew P. Rasdal discloses dealings in 2 companies, chiefly ReShape Lifesciences Inc. and Dexcom Inc. We count 8 filings; the first trade dates from 2 May 2006 and the latest from 6 August 2019.
In open-market terms, that means 1 purchase worth €45k on one side and 1 sale worth €2.4M on the other. Taken together, the sales exceed the purchases by €2.3M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 5 share grants and 1 option exercise. So far in 2019, the count stands at 1 purchase and no sales.
The newest entry dates from 8 August 2019: an open-market purchase of €45k, in ReShape Lifesciences Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Andrew P. Rasdal
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 12,500 shares@ US$4.0019.7% of flowCommon StockSEC:0001214659-19-005089:0Canonical exit: 4 Nov 2019 (T+90)
- 86,957 shares0Common Stock (Restricted Stock Units)SEC:0001214659-19-000146:0
- 109,890 shares@ US$1.8275.0% of flowCommon StockSEC:0001214659-18-005736:0
- 2,987 shares@ US$3.273.2% of flowCommon StockSEC:0001214659-18-003245:0
- 808 shares@ US$7.172.0% of flowCommon StockSEC:0001214659-17-006344:0
- 2,768 shares@ US$9.039.0% of flowCommon StockSEC:0001214659-17-002937:0
- 125,000 shares@ US$0.30Common StockSEC:0001005477-06-002506:0
- 125,000 shares@ US$24.00Common StockSEC:0001005477-06-002506:1
8 of 8 declarations
